Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Atossa Genetics Inc (ATOS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,909
  • Shares Outstanding, K 5,070
  • Annual Sales, $ 0 K
  • Annual Income, $ -8,120 K
  • 36-Month Beta 3.44
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.56

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -0.48
  • Number of Estimates 1
  • High Estimate -0.48
  • Low Estimate -0.48
  • Prior Year -2.04
  • Growth Rate Est. (year over year) +76.47%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.41 +10.64%
on 09/19/18
2.38 -34.45%
on 08/29/18
-0.65 (-29.41%)
since 08/21/18
3-Month
1.41 +10.64%
on 09/19/18
2.88 -45.83%
on 07/09/18
-0.95 (-37.85%)
since 06/21/18
52-Week
1.41 +10.64%
on 09/19/18
19.08 -91.82%
on 10/25/17
-4.68 (-75.00%)
since 09/21/17

Most Recent Stories

More News
Atossa Genetics Announces Preliminary Results from Male Phase 1 Study of Topical Endoxifen

***All Objectives Successfully Met***

ATOS : 1.56 (unch)
Atossa Genetics to Host Conference Call to Announce Preliminary Results from Male Phase 1 Study of Topical Endoxifen Thursday, September 13, 2018 at 10 am EDT

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, will host a conference call...

ATOS : 1.56 (unch)
Atossa Genetics Announces Second Quarter 2018 Financial Results And Provides Company Update

Atossa Genetics Inc. (NASDAQ: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced second...

ATOS : 1.56 (unch)
Automated Services: Are There Hidden Costs to Using Them for a Business?

A CEO is the true overseer of a company. Watching costs and balancing effectiveness is a tough road to walk but if it was easy, anyone would do it. But, could there be such a thing as being too effective?...

ATOS : 1.56 (unch)
Analysis: Positioning to Benefit within Mueller Industries, Eros International, Gannett Co., MarketAxess, Atossa Genetics, and McDonald's -- Research Highlights Growth, Revenue, and Consolidated Results

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Mueller Industries, Inc. (NYSE:MLI),...

EROS : 12.30 (-1.20%)
MKTX : 181.86 (-0.75%)
ATOS : 1.56 (unch)
MLI : 28.53 (+0.11%)
GCI : 10.35 (-0.77%)
MCD : 165.30 (+2.80%)
Investor Expectations to Drive Momentum within NetApp, eBay, The Boeing, HCP, Atossa Genetics, and Anavex Life Sciences -- Discovering Underlying Factors of Influence

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of NetApp, Inc. (NASDAQ:NTAP),...

NTAP : 86.85 (+1.75%)
HCP : 26.39 (+0.15%)
EBAY : 34.04 (-0.58%)
AVXL : 2.49 (-3.11%)
ATOS : 1.56 (unch)
BA : 372.23 (+1.30%)
Atossa Genetics Opens Enrollment in Phase 2 Study of Oral Endoxifen to Treat Breast Cancer

Atossa Genetics Inc. (ATOS) ("Atossa" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today...

ATOS : 1.56 (unch)
Atossa Genetics Opens Its Phase 2 Study of Topical Endoxifen to Treat Mammographic Breast Density

Atossa Genetics Inc. (ATOS) ("Atossa" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today...

ATOS : 1.56 (unch)
Atossa Genetics Completes all Dosing and Clinical Visits in its Phase 1 Study of Topical Endoxifen in Men

Atossa Genetics Inc. (ATOS) ("Atossa" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today...

ATOS : 1.56 (unch)
Atossa Genetics Appoints Two Additional Prominent Industry Executives to Strategic Advisory Board

Atossa Genetics Inc. (NASDAQ:ATOS) ("Atossa" or the "Company"), a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions,...

ATOS : 1.56 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ATOS with:

Business Summary

Atossa Genetics Inc. is a healthcare company focused on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer. The Company's diagnostic tests consist of medical devices which can collect fluid samples from the breast milk ducts. It is also conducting...

See More

Key Turning Points

2nd Resistance Point 1.64
1st Resistance Point 1.60
Last Price 1.56
1st Support Level 1.52
2nd Support Level 1.48

See More

52-Week High 19.08
Fibonacci 61.8% 12.33
Fibonacci 50% 10.24
Fibonacci 38.2% 8.16
Last Price 1.56
52-Week Low 1.41

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar